$OLMA

Olema (NASDAQ: OLMA) director granted 27,061 stock options

Olema Pharmaceuticals director Raman Prakash has been granted 27,061 stock options as equity compensation, with an exercise price of $14.59 per share, expiring on April 27, 2036. The options vest based on continuous service, with one portion vesting in full on June 11, 2026, and another in 36 equal monthly installments starting April 28, 2026. This transaction reflects compensation rather than open-market purchases.

Original reporting
Published Apr 29, 2026, 11:38 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 30, 2026, 7:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$OLMA
Neutral
medium confidence
Mentioned
$OLMA
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$OLMANeutralLow
01

Why it matters

While indicative of insider confidence, the transaction alone is unlikely to cause significant market movement without supporting news or price action.

02

Market read

This internal compensation event has limited immediate trading relevance but may be of interest to investors monitoring insider activities.

03

What to watch

Market conditions, upcoming catalysts, or broader biotech sector trends could overshadow this internal transaction in influencing stock price.

Timing: short-term

Background

Olema Pharmaceuticals' insider granted stock options as part of compensation, with scheduled vesting and an exercise price of $14.59.

Company-level read

Ticker impact

$OLMANeutralMedium confidence
Context

The news pertains to insider stock option grants for Olema Pharmaceuticals, which could influence stock perception.

Expected impact

Potential slight upward movement in stock price if current price is below or near $14.59; limited impact if already above.

Evidence & confidence

Insider option grants are common and may reflect confidence, but as a compensation transaction, they do not guarantee future performance.

Market effects

The news is specific to Olema's internal compensation and unlikely to influence the broader biotech or life sciences sector.

Minimal regional impact; limited to company-specific events.

Negligible

Counterpoint

Insider stock option grants can sometimes be a sign of insiders hedging their positions or preparing for future dilution, which might negatively impact the stock.

Key entities

  • Olema Pharmaceuticals

    A biotech company focused on developing targeted therapies.

Related articles

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.

$NOCMed

WP: Pentagon asks defense companies to urgently ramp up weapons production

The Pentagon, via Deputy Secretary Steve Feinberg, urged U.S. defense firms to accelerate weapons output, especially ammunition, and asked executives to submit production and delivery plans within 21 days, according to The Washington Post. CSIS data cited Patriot and THAAD stockpiles falling sharply. The article notes talks with Northrop Grumman and Lockheed Martin and a Lockheed contract up to $58.6B to triple PAC-3 output by 2030.